HPS Pharmacies wish to advise that Mayne Pharma, in conjunction with the Therapeutic Goods Administration (TGA) has issued an urgent medicine quarantine of Linezolid MYX™ Injection as follows:
Linezolid MYX™ Injection
Linezolid 600mg/300mL infusion bag
The affected lot is ZW701 with an expiry date of February 2019.
The quarantine pertains to reports of possible mould on the infusion bags contained within the outer foil packaging. Infusion bags from the abovementioned lot must not be used until further investigation confirms or explains the reports. As a precaution, any other lots of this product should also be quarantined. HPS Pharmacies will provide an update as more information comes to hand.
Like all parenteral products, it is important to remember to visually inspect each product before use. Each IV bag should undergo a manual ‘squeeze test’ immediately prior to use to ensure there are no leaks. If moisture, mould, or any other anomaly is detected, that bag must be quarantined.
Please inspect your stock and quarantine all Linezolid MYX™ infusion bags. If HPS Pharmacies provide imprest management services to your facility, an HPS representative will inspect all stock stored in the designated imprest areas at the earliest opportunity. All affected products will be quarantined until further instructions are received from Mayne Pharma and the TGA. An HPS Pharmacies staff member will contact senior medical and nursing staff if there is an immediate impact to your facility.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies, or Mayne Pharma on 1300 081 849.